UK guidance log · O-052
MHRA peptide advertising updates
Guidance explains the regulator's view; legislation supplies the legal rules. This log keeps the current GN8, medicines advertising guidance and Blue Guide versioned without presenting them as a new peptide-specific statute.
The MHRA record checked on 11 August 2026 includes Guidance Note 8, the medicines advertising guidance, the Blue Guide and advertising decisions published on 5 August 2026.
The July decisions apply existing UK medicines law to indirect promotion of prescription-only weight-loss medicines and promotion before UK marketing authorisation. They do not create a separate peptide-specific legal category.
What is current in the MHRA record
The dates below describe the official source record. They do not imply that every file was substantively revised on the date a hosting endpoint changed.
| Source | Current dated record | What it governs or explains | Status |
|---|---|---|---|
| MHRA Guidance Note 8 | Published September 2025 | How MHRA decides whether a product is a medicine, including presentation, function and online context | Guidance, not legislation |
| Advertise your medicines | Updated 11 April 2025 | Core restrictions, including unlicensed medicines and public advertising of prescription-only medicines | Official guidance on legal requirements |
| Blue Guide publication page | Updated 28 March 2025 | Detailed UK advertising and promotion guidance, including the current appendix record | Guidance tied to medicines law |
| Advertising investigations: weight-loss treatment services | Published 5 August 2026 | Seven providers amended advertising after MHRA action on direct or indirect public promotion of prescription-only weight-loss medicines | Named decision record |
| Human Medicines Regulations 2012 | Current legislation must be checked at source | Legal definition of a medicinal product and advertising prohibitions | Legislation |
The practical position for peptide advertising
MHRA assesses products case by case. A product can fall within the medicinal definition because of the way it is presented or because of its function. Names, disease or recovery claims, testimonials, instructions, imagery and linked sales material can all form part of the presentation.
An unlicensed medicine cannot be advertised. A prescription-only medicine cannot be advertised to the public. A “research use only” line does not erase conflicting human-use claims elsewhere in the customer journey.
5 August 2026: weight-loss advertising decisions
MHRA published both decisions on 5 August 2026. The actions took place in July, but the decision pages do not give exact action dates.
| Decision | MHRA finding | Recorded outcome |
|---|---|---|
| Seven weight-loss treatment-service providers | The advertising directly or indirectly referred to weight-loss injections or GLP-1 medication in a way likely to lead a member of the public to request a prescription-only medicine. | The seven providers amended the named advertising following MHRA action on complaints. |
| Phlo Clinic “early access” email | MHRA considered that the email promoted GLP-1 weight-loss products before they held UK marketing authorisation for that indication. | Phlo confirmed that it withdrew the advertisement, that it was no longer in use and that it would comply with the regulations and MHRA guidance. |
These are completed outcomes for named adverts, not claims of an ongoing breach. Read how indirect prescription-only medicine promotion is assessed and why pre-authorisation promotion is prohibited.
Keep guidance, legislation and product decisions separate
The source type determines how strong a conclusion can be.
| Layer | Defensible use | Do not claim |
|---|---|---|
| Human Medicines Regulations 2012 | Cite the applicable legal definition or prohibition | That a guidance note created the legislation |
| GN8 and Blue Guide | Explain MHRA's published interpretation and practical factors | That guidance is a court judgment or product authorisation |
| MHRA borderline opinion | Record the agency's non-statutory view on the material submitted | That “not medicinal” is approval to sell, supply or advertise |
| Product-specific enforcement | Cite the named notice, decision or case | Extend it automatically to every product using the same molecule name |
Where the current guidance applies on this site
Use the framework page for legal structure and the advertising note for claim-level examples.
- the current UK positionSee classification, authorisation, supply and reporting routes in one framework.
- how advertising rules apply nowReview explicit and implied claims, testimonials, influencers, links and disclaimers.
- why the disclaimer is not decisiveCompare a label with the complete presentation and sales route.
- report a questionable promotion or sellerPreserve the dated claim and use the appropriate regulator route.
- the UK guidance logCheck any substantive correction to this record.
Primary source ledger
All sources were checked on 11 August 2026. File publication dates and webpage update dates are recorded as the source states them.
| Source | What it establishes | What it does not establish |
|---|---|---|
| MHRA Guidance Note 8 | Current published factors for deciding whether a product is medicinal, with its own status caveat | A binding ruling for every peptide product |
| MHRA: advertise your medicines | Core official restrictions and links to the statutory framework | Permission for a particular advertisement |
| MHRA Blue Guide publication page | The current guide and its update record | A substitute for the underlying legislation |
| MHRA: medicinal treatment services for weight loss, July 2026 | Seven providers amended named adverts following MHRA action on public promotion of prescription-only weight-loss medicines | An allegation that the named adverts remain in use or that the decision endorses wider provider practices |
| MHRA: Phlo Clinic pre-authorisation promotion, July 2026 | MHRA's assessment of the “early access” email and Phlo's confirmation that it was withdrawn | An allegation that the email remains in use or a judgment about unrelated Phlo advertising |
| Human Medicines Regulations 2012, regulation 2 | The legal definition of medicinal product | A product-specific classification without applying the facts |
| Human Medicines Regulations 2012, regulation 279 | The GB prohibition on advertising a medicine without the required authorisation or registration | A complete account of every advertising rule or exception |
| MHRA borderline advice request | The scope and limits of a non-statutory MHRA opinion | Approval to sell, supply or advertise a product |
Update protocol
This log is checked monthly and when MHRA or GOV.UK publishes a revised GN8, Blue Guide, advertising page or relevant enforcement notice. A file-hosting date alone is not treated as a substantive policy change.
If the official source changes, we record the new version, what changed and which pages need review. Corrections remain visible rather than being hidden behind a new modified date.
MHRA guidance questions
Did the MHRA create a new peptide advertising law in 2026?
We did not identify a peptide-specific 2026 law in the sources reviewed. The current guidance explains how existing medicines legislation applies to product presentation and advertising.
Is MHRA Guidance Note 8 legislation?
No. GN8 is official guidance on how MHRA approaches borderline product classification. The document states that it is not definitive law and does not replace legal advice.
Can an unlicensed peptide medicine be advertised?
MHRA guidance states that an unlicensed medicine cannot be advertised. A product's classification depends on its presentation, function and the full facts.
Can a prescription-only medicine be promoted to the public?
No. UK medicines advertising rules prohibit public advertising of prescription-only medicines. Professional promotion is governed by a separate set of requirements.
Does a “research use only” label remove a medicinal claim?
No. The whole presentation matters. Human-use claims, testimonials, images, instructions and linked purchasing material can conflict with the disclaimer.
Does an MHRA “not medicinal” opinion approve a product?
No. MHRA's borderline advice form says such an opinion does not approve the sale, supply or advertising of the product. Other legal regimes may still apply.
Editorial experience
From our work: how we checked this page
For topical-map item O-052, MHRA peptide advertising guidance: current update log was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 8 unique external sources and 9 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Yianni Kiromitis checked the page against its mapped purpose, verified the cited sources, reviewed the internal routes and approved the final wording as Lead Author, Publisher and Managing Editor. This page does not carry a specialist review credit because its publication decision did not require a scientific or clinical conclusion beyond the named material it links to.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.